GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » Cash Flow from Investing

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Cash Flow from Investing : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2023, RespireRx Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, RespireRx Pharmaceuticals gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2023.


RespireRx Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for RespireRx Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RespireRx Pharmaceuticals Cash Flow from Investing Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

RespireRx Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

RespireRx Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

RespireRx Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Sep. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RespireRx Pharmaceuticals  (OTCPK:RSPI) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

RespireRx Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means RespireRx Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

RespireRx Pharmaceuticals's sale of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means RespireRx Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

RespireRx Pharmaceuticals's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means RespireRx Pharmaceuticals spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

RespireRx Pharmaceuticals's sale of business for the three months ended in Sep. 2023 was $0.00 Mil. It means RespireRx Pharmaceuticals gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

RespireRx Pharmaceuticals's purchase of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means RespireRx Pharmaceuticals spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

RespireRx Pharmaceuticals's sale of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means RespireRx Pharmaceuticals gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

RespireRx Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Sep. 2023 was $0.00 Mil. It means RespireRx Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

RespireRx Pharmaceuticals's cash from discontinued investing activities for the three months ended in Sep. 2023 was 0.00 Mil. It means RespireRx Pharmaceuticals paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

RespireRx Pharmaceuticals's cash from other investing activities for the three months ended in Sep. 2023 was $0.00 Mil. It means RespireRx Pharmaceuticals paid $0.00 Mil for other investing activities.


RespireRx Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.
Executives
David Dickason officer: SVP of Pre-Clinical Prod. Dev. 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones director, officer: CEO and President 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J director, officer: President & CEO 5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr. officer: SVP - Research & Deleopment 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin officer: Controller 33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten director, officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc other: Member of a 10% owner group 354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp other: Member of 10% owner group
Jeff Eliot Margolis director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik other: Member of 10% owner group C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa director, officer: Chairman, CEO and President, other: Member of 10% owner group C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen other: Member of 10% owner group 12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Headlines

From GuruFocus